









Markets
/
Stocks
/
nasdaq-ptct
/

PTC Therapeutics Inc

PTCT

66.430USD

-0.320-0.48%

Market hours （ET）Quotes delayed by 15 min

5.31BMarket Cap

8.04P/E TTM



PTC Therapeutics Inc

66.430

-0.320-0.48%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of PTC Therapeutics Inc

Currency: USD Updated: 2026-03-26

Key Insights

PTC Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 87.07.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PTC Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

20 / 157

Overall Ranking

73 / 4546

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

PTC Therapeutics Inc Highlights

StrengthsRisks

PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 84.54% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 7.81, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 85.87M shares, decreasing 4.24% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 16.23K shares of this stock.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

87.067

Target Price

+34.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of PTC Therapeutics Inc is 7.14, ranking 121 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 164.68M, representing a year-over-year decrease of 22.75%, while its net profit experienced a year-over-year decrease of 104.85%.

Score

Industry at a Glance

Previous score

7.14

Change



Financials

5.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.20

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

PTC Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of PTC Therapeutics Inc is 8.42, ranking 18 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 7.81, which is 15.75% below the recent high of 9.04 and 254.91% above the recent low of -12.09.

Score

Industry at a Glance

Previous score

8.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 20/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of PTC Therapeutics Inc is 7.60, ranking 101 out of 157 in the Pharmaceuticals industry. The average price target is 80.00, with a high of 118.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

7.60

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Buy

Current Rating

87.067

Target Price

+34.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

PTC Therapeutics Inc

PTCT

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of PTC Therapeutics Inc is 8.88, ranking 19 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 71.52 and the support level at 61.95, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.44

Change

1.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.754

Neutral

RSI(14)

48.900

Neutral

STOCH(KDJ)(9,3,3)

55.146

Neutral

ATR(14)

3.037

Low Volatility

CCI(14)

36.083

Neutral

Williams %R

45.096

Neutral

TRIX(12,20)

-0.234

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

66.002

Buy

MA10

66.273

Buy

MA20

65.906

Buy

MA50

70.098

Sell

MA100

73.163

Sell

MA200

64.044

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of PTC Therapeutics Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 106.95%, representing a quarter-over-quarter increase of 7.44%. The largest institutional shareholder is The Vanguard, holding a total of 8.79M shares, representing 10.61% of shares outstanding, with 2.09% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.69M

-1.77%

The Vanguard Group, Inc.

Star Investors

8.27M

-6.30%

RTW Investments L.P.

7.75M

Janus Henderson Investors

3.77M

+18.85%

State Street Investment Management (US)

3.13M

+4.62%

TD Securities, Inc.

3.25M

+32.73%

Wellington Management Company, LLP

4.92M

+4.78%

Armistice Capital LLC

3.28M

-30.79%

Geode Capital Management, L.L.C.

1.95M

+0.84%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of PTC Therapeutics Inc is 6.71, ranking 48 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. PTC Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.